Kazia Therapeutics (KZIA) is pleased to announce the regulatory approval and launch of a clinical trial evaluating the combination of paxalisib and immunotherapy in patients with advanced breast cancer. This novel treatment combination offers what is believed to be a unique approach to targeting this highly aggressive and treatment-resistant type of breast cancer. The ABC-Pax study is the first known trial conducted to assess the safety and efficacy of paxalisib in combination with KEYTRUDA or LYNPARZA in women with triple negative breast cancer. ABC-Pax is a multi-centre, open-label phase 1b study that will enroll 24 patients from top cancer centres in Queensland, Australia and patients will receive the combination therapy for up to 12 months.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KZIA:
- Kazia Therapeutics Issues Prefunded Warrant for ADS Purchase
- Kazia Therapeutics to sell 1.33M ADS at $1.50 in registered direct offering
- Kazia Therapeutics Charts Path Forward for Paxalisib After FDA Feedback
- Kazia announces FDA says OS data supports standard, not accelerated approval
- Kazia Therapeutics Presents Promising Data on Paxalisib for Breast Cancer Treatment